Company Overview
Canopy Growth Corporation operates as a producer, distributor, and seller of cannabis, hemp, and cannabis-related products across its primary markets in Canada, Germany, and Australia. The company functions within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized therapeutic compounds and regulated pharmaceutical distribution channels. The entity employs a workforce of 960 individuals and maintains a total market capitalization of $437.00M with a trailing twelve-month revenue of $278.39M. These valuation and revenue figures indicate that the company operates as a mid-sized market participant that has faced significant headwinds, resulting in a market cap that is substantially lower than the revenue base, suggesting the market prices the stock heavily on future regulatory or operational potential rather than current earnings power.
Financial Health
The company reported a revenue of $278.39M over the trailing twelve months, yet this top-line activity generated a net income of $-327,294,016 and an EBITDA of $-8,742,000. The substantial gap between the positive revenue of $278.39M and the negative net income reveals a highly aggressive cost structure where operating expenses significantly exceed gross profits, erasing all profitability from sales. Free cash flow stands at $-25,979,250, indicating that the company is burning cash operations rather than generating liquidity, which limits its financial flexibility to fund expansion without external capital raises. Profitability analysis shows a gross margin of 26.6%, an operating margin of -17.6%, and a profit margin of -117.3%, where the negative operating and profit margins demonstrate that overhead costs and other expenses are consuming more than 100% of the gross profit generated. On the balance sheet, Canopy Growth holds $371.48M in cash against $255.12M in debt, resulting in a debt-to-equity ratio of 33.65, which suggests a leveraged position where debt obligations are nearly one-third of the equity base. However, the current ratio of 5.34 indicates a strong liquidity position relative to short-term obligations, as the company holds significantly more current assets than current liabilities. Return on equity is -48.5% and return on assets is -2.6%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Valuation Assessment
Valuation multiples reflect the company's lack of profitability, with a P/E Ratio (TTM) listed as N/A due to negative earnings and a forward P/E of -13.32. The negative forward P/E implies that the market is pricing in a trajectory where earnings are expected to remain negative or require a significant turnaround to become positive in the near term. The price-to-book ratio is 0.65, indicating that the stock trades at a discount to its book value, suggesting the market values the company at less than the replacement cost of its net assets. Alternative valuation metrics include a price-to-sales ratio of 1.57 and an EV/EBITDA of -28.75, which suggest the market is valuing the firm based on sales multiples rather than earnings power, a common practice for companies in the red. The stock has traded between a 52-week high of $2.38 and a 52-week low of $0.77, with the current price sitting at a level that reflects a deep discount from the recent high and a significant recovery from the low. The beta of 2.34 indicates that the stock price is highly volatile, moving with more than twice the magnitude of the broader market, which introduces substantial risk for investors seeking stability.
Growth & Income
Revenue growth year-over-year is -0.3%, while earnings growth is listed as N/A due to the lack of profitable earnings history to compare against. Since earnings are negative, they cannot grow faster than revenue in a traditional sense; the company is struggling to convert sales into profit rather than expanding its bottom line. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividends confirms that the company is retaining all available cash to fund operations and potentially reduce its debt load rather than distributing income to shareholders. The overall growth and income profile is characterized by negative revenue growth and a complete lack of dividend income, positioning the asset as a high-risk equity instrument with no current income stream.